CAI — Stock Film
STOCK FILMSCENE 1/11CAI · $16.49
Stock Expert AI presents
CAI
Caris Life Sciences, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Caris Life Sciences, Inc. A quick introduction.

On the stock market since 2025, it operates in the world of health and science. It has 1,846 employees. Now — the numbers.

on the stock market since 2025
1,846 employees
$4.7B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.7.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 29% a year over the last 4 years. Red columns mark years that ended in a loss.

$294M
2020
$258.5M
2022
$306.1M
2023
$412.3M
2024
$812M
2025
In the vault right now:
$0
DEBT: $379.0M
At this pace, that money lasts about 1.5 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
90
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
91
very strong

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
66
strong

Clearly above the class average — a step short of the very top.

GROWTH
50
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
22
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Costs eat into the margin4/10
WORTH WATCHING

Cost Efficiency: As sales grow, profit fails to keep the same pace.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 58% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 46% a year on average.

2
THE BRIGHT SIDE · 2/3
Sales are holding up

The company sells $812.0M a year; the problem isn’t sales — it’s costs running above that number.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $25.0052% above today’s price.

1
THE RISKS · 1/2
The losses continue

A loss of $538.0M against $812.0M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.

FINALE · THE GRADE
B
0 / 100 · MoonshotScore

On our five-subject report card, CAI sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: CAI has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film